Results 11 to 20 of about 2,022,996 (246)

Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

Genome Medicine, 2019
Background The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden.
Jitske van den Bulk, Els M. E. Verdegaal, Dina Ruano, Marieke E. Ijsselsteijn, Marten Visser, Ruud van der Breggen, Thomas Duhen, Manon van der Ploeg, Natasja L. de Vries, Jan Oosting, Koen C. M. J. Peeters, Andrew D. Weinberg, Arantza Farina-Sarasqueta, Sjoerd H. van der Burg, Noel F. C. C. de Miranda   +14 more
doaj   +2 more sources

Ectopic HLA-II Expression in ESCC: Exploration of Its Relationship with Neoantigen Burden and Patient Survival [PDF]

Cells
Ectopic expression of human leukocyte antigen class II (HLA-II) on tumor cells correlates with anti-tumor immunity and prognosis in various cancers, but its role in esophageal squamous cell carcinoma (ESCC) remains unclear. Methods: HLA-II expression was
Yupei Ji, Zhizhong Wang, Zhenguo Cheng, Shuangshuang Lu, Nick R. Lemoine, Renato Baleeiro, Louisa S. Chard Dunmall, Yaohe Wang   +7 more
doaj   +2 more sources

NeoPredPipe: high-throughput neoantigen prediction and recognition potential pipeline [PDF]

BMC Bioinformatics, 2019
Background Next generation sequencing has yielded an unparalleled means of quickly determining the molecular make-up of patient tumors. In conjunction with emerging, effective immunotherapeutics for a number of cancers, this rapid data generation ...
Ryan O. Schenck, Eszter Lakatos, Chandler Gatenbee, Trevor A. Graham, Alexander R.A. Anderson   +4 more
doaj   +2 more sources

Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine [PDF]

Cancer Immunology Research
Abstract Tumor neoantigens (nAg) represent a promising target for cancer immunotherapy. The identification of nAgs that can generate T-cell responses and have therapeutic activity has been challenging. Here, we sought to unravel the features of nAgs required to induce tumor rejection.
Irene Garzia, Linda Nocchi, Lidia Avalle, Fulvia Troise, Guido Leoni, Laura Seclì, Laura Antonucci, Gabriella Cotugno, Simona Allocca, Giuseppina Romano, Laura Conti, Carmen Caiazza, Massimo Mallardo, Valeria Poli, Elisa Scarselli, Anna Morena D'Alise   +15 more
openaire   +7 more sources

The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives

Journal of Hematology & Oncology
Cancer immunotherapy has revolutionized oncology by leveraging the immune system to combat tumors. Among various biomarkers, neoantigens and tumor mutational burden (TMB) have emerged as critical factors in tailoring personalized treatments.
Shengbo Sun, Lanchun Liu, Jingkang Zhang, Liting Sun, Wenlong Shu, Zhengyang Yang, Hongwei Yao, Zhongtao Zhang   +7 more
doaj   +3 more sources

Supplementary Table from Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms

, 2021
Supplementary Table from Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance ...
Pamela Milani (470521), Rachel Marty Pyke (15033824), Michael P. Snyder (15033839), Eric Levy (3713023), Dattatreya Mellacheruvu (531667), Sekwon Jang (8899451), Fábio C.P. Navarro (15033827), Mengyao Tan (14933070), Richard Chen (819249), Simo V. Zhang (6103124), Jason Harris (60019), Charles W. Abbott (9402235), Gabor Bartha (3549785), Lee D. McDaniel (4033088), Rose Santiago (15033830), Sean M. Boyle (15033821), Zeid M. Rusan (15033833), Rena McClory (15033836)   +17 more
core   +8 more sources

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product

Scientific Reports
Retrospective data support overall survival (OS) advantage to high clonal tumor mutation burden (cTMB), high clonal neoantigen load (cNEO) and low intratumor heterogeneity (ITH) in cancer patients who receive immunotherapy.
David Willoughby, Ernest Bognar, Laura Stanbery, Casey Nagel, Gladice Wallraven, Aman Pruthi, Nicholas Bild, Ericca Stamper, Donald Rao, Adam Walter, John Nemunaitis   +10 more
doaj   +3 more sources

Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas [PDF]

Cancers, 2021
Background: A consistent correlation between tumor mutation burden (TMB) and tumor immune microenvironment has not been observed in gliomas as in other cancers. Methods: Driver germline and somatic mutations, TMB, neoantigen, and immune cell signatures were analyzed using whole exome sequencing (WES) and transcriptome sequencing of tumor and WES of ...
Guangyang Yu, Ying Pang, Mythili Merchant, Chimene Kesserwan, Vineela Gangalapudi, Abdalla Abdelmaksoud, Alice Ranjan, Olga Kim, Jun S. Wei, Hsien-Chao Chou, Xinyu Wen, Sivasish Sindiri, Young K. Song, Liqiang Xi, Rosandra N. Kaplan, Terri S. Armstrong, Mark R. Gilbert, Kenneth Aldape, Javed Khan, Jing Wu   +19 more
openaire   +2 more sources

SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors

Cancer Research Communications, 2023
Abstract Aberrant alternative splicing can generate neoantigens, which can themselves stimulate immune responses and surveillance. Previous methods for quantifying splicing-derived neoantigens are limited by independent references and potential batch effects.
Theron Palmer, Michael D. Kessler, Xiaoshan M. Shao, Archana Balan, Mark Yarchoan, Neeha Zaidi, Tamara Y. Lopez-Vidal, Ali M. Saeed, Jessica Gore, Nilofer S. Azad, Elizabeth M. Jaffee, Alexander V. Favorov, Valsamo Anagnostou, Rachel Karchin, Daria A. Gaykalova, Elana J. Fertig, Ludmila Danilova   +16 more
openaire   +2 more sources

Transcriptomic-Assisted Immune and Neoantigen Profiling in Premalignancy [PDF]

, 2022
Immune-based cancer therapies such as checkpoint inhibitors (CPI) and vaccines have been increasingly studied across different cancer types. Response to such therapies depends on a number of factors such as mutational burden, neoantigen load, presence of
Kyle Chang, Vilar, Eduardo, Eduardo Vilar, McAllister, Florencia, Florencia McAllister, Chang, Kyle   +5 more
core   +1 more source